ACT EU workshop on multiplicity in confirmatory clinical trials: From two-arm to platform trials , Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 27 November 2026, 09:00 (CET) to 27 November 2026, 15:00 (CET)

Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (21 August 2026 - 17 September 2026)

Suboxone : EPAR - Procedural steps taken before authorisation

Suboxone : EPAR - Procedural steps taken before authorisation

PSUSA/00010431/202510

Human medicines European public assessment report (EPAR): Ruxolitinib Viatris, ruxolitinib hemifumarate, Date of authorisation: 18/09/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Nezglyal, leriglitazone, Date of authorisation: 21/09/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Jorveza, budesonide, Date of authorisation: 08/01/2018, Revision: 8, Status: Authorised

Article 57 product data

Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 10, Status: Authorised